Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.86 USD | +8.24% | +9.82% | +168.37% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 134.97 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.69 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+168.37% | 4.73B | - | ||
+78.57% | 584M | - | - | |
-3.74% | 443M | - | ||
-71.50% | 124M | C- | ||
-28.20% | 91M | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HIMS Stock
- Ratings Hims & Hers Health, Inc.